First-Line Treatment of Microfilariae-Positive Lymphatic Filariasis
Lymphatic filariasis (ICD-11 1F66.3 / ICD-10 B74) is a parasitic infection diagnosed when microfilariae (Mf) are detected in blood — confirmed by night blood survey (NBS) or filariasis test strip (FTS). Cases identified through surveillance surveys or at health-care facilities require prompt structured antifilarial treatment under direct observation.
Treatment Approach
The protocol opens with a directly observed single-dose antifilarial combination on day 1, given in line with the national Mass Drug Administration (MDA) schedule. Two regimen options are defined — one a two-drug combination, the other a three-drug combination — with the choice guided by the schedule. This day-1 dose is followed by a further oral treatment course to consolidate parasiticidal effect.
The full regimen — including which combination applies, dosing, and complete course duration — is available in the structured protocol below.
Clinical Goals
The primary target is clearance of microfilariae from the bloodstream, confirmed as Mf-negative on repeat blood testing. Patients are followed up with repeat testing every six months until Mf-negative status is established and sustained.
References
- All Mf positive cases confirmed by NBS or FTS test would be treated with Directly Observed single dose of DA or IDA as per the MDA schedule, followed by standard DEC of dosage 6mg/Kg body weight daily for 12 days to be consumed after the meal.
- The positive cases that are detected in the health care facilities or during NBS surveys and TAS surveys, need to be treated with Directly Observed Single dose of DA or IDA (Day 1) as per the MDA schedule, followed by standard treatment with DEC of dosage 6mg/Kg body weight daily for 12 days to be consumed after the meal and ensure follow up of such cases.
- Each positive case to be followed up with repeat testing for every 6 months (if positive) to be done till they are Mf negative.
View source ↗